Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death

被引：0
作者：
Jan O Friedrich
Neill KJ Adhikari
Maureen O Meade
机构：
[1] St. Michael's Hospital,Critical Care and Medicine Departments
[2] Interdepartmental Division of Critical Care,Department of Critical Care Medicine
[3] University of Toronto,Departments of Medicine and Clinical Epidemiology & Department of Critical Care
[4] Sunnybrook Health Sciences Centre,undefined
[5] Interdepartmental Division of Critical Care,undefined
[6] University of Toronto,undefined
[7] Biostatistics,undefined
[8] McMaster University,undefined
[9] Hamilton Health Sciences,undefined
来源：
Critical Care | / 10卷
关键词：
Random Effect; Severe Sepsis; Health Evaluation; Fixed Effect Model; Methodologic Difference;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 33 条
[1]  
Williams MD(2006)Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death Crit Care 10 424-709
[2]  
Janes JM(2006)Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis? Crit Care 10 145-1341
[3]  
Nelson DR(2001)Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 344 699-560
[4]  
Friedrich JO(2005)Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death N Engl J Med 353 1332-undefined
[5]  
Adhikari NK(2006)Drotrecogin alfa (activated): down and not out, but not really in either Crit Care 10 420-undefined
[6]  
Meade MO(2003)Measuring inconsistency in meta-analyses BMJ 327 557-undefined
[7]  
Bernard GR(undefined)undefined undefined undefined undefined-undefined
[8]  
Vincent JL(undefined)undefined undefined undefined undefined-undefined
[9]  
Laterre PF(undefined)undefined undefined undefined undefined-undefined
[10]  
LaRosa SP(undefined)undefined undefined undefined undefined-undefined
1234